Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,994.00
Bid: 1,750.00
Ask: 2,222.00
Change: 0.00 (0.00%)
Spread: 472.00 (26.971%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,994.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Johnston Press, Direct Line, Hikma Pharmaceuticals

Thu, 04th Aug 2016 11:01

(ShareCast News) - Johnston Press shares plunged on Thursday as Numis placed its rating and target price 'under review' after the company swung to a first half loss.For the 26 weeks to 2 July, the company posted a statutory pre-tax loss of £183.7m versus a £2.2m profit the year before, as it booked a £183.6m non-cash impairment reflecting a change of assumptions on its publishing titles and print assets.Advertising revenues were down 17.9% in the first quarter but improved marginally, with a 15% drop in the second quarter despite the impact of the run-up to and uncertainty following the UK's vote to leave the European Union in June.Chief executive Ashley Highfield said the market continues to be challenging and uncertainty surrounding the outcome of the Brexit negotiations has caused further softness in some segments of the advertising market, in June and July.Numis said the half year results came in below its estimates at every level."Our key issue at Johnston remains debt which has risen to £209m (from £179.4m) representing almost 4x our annualised EBITDA."This material debt pile, relative to cashflows, in combination with the declining and uncertain trading environment place a significant question mark on the equity value in the business."Numis said it expects to cut estimates "reasonably sharply" in both fiscal years 2016 and 2017. Direct Line Insurance Group's rating has been downgraded to 'hold' from 'buy' by Berenberg as the broker said "questions remain about earnings sustainability"."We believe there is some risk regarding the sustainability of Direct Line's earnings," Berenberg said in a note on Wednesday."High reserve releases, lower than forecast cost savings and a shrinking direct market all cast doubt on future earnings."Berenberg said older accident years have been incredibly profitable for Direct Line but these years are now contributing increasingly less releases.The broker said it does not expect to see the same developments in more recent accident years. Berenberg believes it will be difficult for management to offset falling reserve releases with the current accident year and operating improvements."As reserve releases decline, we expect earnings to be flat at best, thus we believe it will be challenging to grow the dividend from here," the broker said.Berenberg reiterated a target price of 406p.Direct Line on Tuesday posted its half year report for the six months to 30 June on Tuesday. Operating profit fell 5% to £316.9m, hurt by lower investment gains and the new Flood Re levy, but the group beat its own consensus estimates of £263m. Analysts at Citi downgraded their recommendation on shares of Hikma Pharmaceuticals in the wake of the company´s trading update which was issued after the close of trading in London on 3 August.Hikma flagged new drug approvals were arriving more slowly than expected and the phasing of litigation costs at US generics.On the basis of the above, the broker´s analysts lowered their recommendation on the shares from 'buy' to 'neutral' and set a target price of 2,600p.They also lowered estimates for the drugmaker´s core 2016 earnings before interest and taxes and earnings per share by 9.0% to $367m and $1.08, respectively - below the equivalent figures of $420m and $1.22 expected by the consensus.EPS estimates from 2017 onwards were cut by between 2% and 5% from 2017 onwards, with rates in foreign exchange markets expected to be an "incremental headwind".What was Citi´s view? "Developments at US Generics at best can be described as a 'short term hiccup'. At worse, sentiment concerns around the revenue/margin potential from the Roxane pipeline will increase, which is not helped by the lack of clarity on the pipeline given commercial sensitivities until 2017."If one were to cut his Roxane pipeline estimates by half, that would lead to EPS downgrades of between -15.0% and -20.0%, Citi said.Citi estimated the company´s net present value (NPV) at 2,900p, with a weighted average cost of capital of 8.0%, a terminal growth value (the rate at which free cash flows are expected to grow for eternity) of 2.0% and cable´s exchange rate at 1.32.
More News
25 Feb 2021 08:47

LONDON MARKET OPEN: FTSE 100 Edges Up As Fed's Powell Soothes Markets

LONDON MARKET OPEN: FTSE 100 Edges Up As Fed's Powell Soothes Markets

Read more
25 Feb 2021 08:38

TOP NEWS: Hikma Hikes Dividend Amid Growth From All Three Businesses

TOP NEWS: Hikma Hikes Dividend Amid Growth From All Three Businesses

Read more
25 Feb 2021 08:02

UPDATE 2-UK's Hikma misses profit estimate, disappoints on 2021 outlook, share tumbles

* Core operating profit of $566 mln vs consensus of $574 mln* 2021 outlook weaker than analyst expectation* Shares drop nearly 7% (Recasts, adds shares, CEO and analyst comments)By Tanishaa Nadkar and Pushkala AripakaFeb 25 (Reuters) - Hikma Pharmac...

Read more
25 Feb 2021 08:01

LONDON MARKET PRE-OPEN: ABF's Primark Loses GBP1.1 Billion In Sales

LONDON MARKET PRE-OPEN: ABF's Primark Loses GBP1.1 Billion In Sales

Read more
18 Feb 2021 15:58

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
15 Feb 2021 09:40

BROKER RATINGS: Bernstein Lifts Reckitt; Liberum Cuts Moneysupermarket

BROKER RATINGS: Bernstein Lifts Reckitt; Liberum Cuts Moneysupermarket

Read more
3 Feb 2021 09:17

UPDATE 2-Healthcare drags FTSE 100 down; Vodafone jumps

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* GlaxoSmithKline slumps on COVID-19 vaccine development* Vodafone gains after earnings beat estimates* Glencore rises after maintaining 2021...

Read more
1 Feb 2021 13:44

Monday broker round-up

(Sharecast News) - Polymetal International: Berenberg reiterates buy with a target price of 2,310p.

Read more
26 Jan 2021 08:28

TOP NEWS: Hikma In Talks To Buy Glaxo Businesses In Egypt And Tunisia

TOP NEWS: Hikma In Talks To Buy Glaxo Businesses In Egypt And Tunisia

Read more
12 Jan 2021 10:13

Vectura Forecasts 2020 Earnings To Top Board Expectations

Vectura Forecasts 2020 Earnings To Top Board Expectations

Read more
18 Dec 2020 17:08

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 10:45

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

Read more
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.